Abstract:Objective To evaluate the sensitivity and specificity of new genevation Beckman Coulter cTnI in diagnosis of non-ST-elevation myocardial infarction(NSTEMI),and the values of cTnI in prognosis of non-ST elevation acute coronary syndromes(NSTEACS).Methods The cTnI was determined in NSTEMI patients and in control group,then analyzed the data with receiver operating characteristic curve (ROC curve)statistical software.Two hundred and sixty-nine patients with non-ST elevation acute coronary syndromes were divided into cTnI≥0.04 μg/L and cTnI<0.04 μg/L.Acute myocardial infarction and/or cardiac mortality were observed in all patients through both 30 days and 1 year of follow-up.Results The area under the ROC curve was 0.95.The optimal cut-off was 0.1 μg/L in the diagnosis of NSTEMI and the sensitivity and specificity was 91.4% and 89.3%.The sensitivities and specificities of creatine kinase, creatine kinase MB,lactate dehydrogenase and α-hydroxybutyrate dehydrogenase were less poor than that of cTnl.By univariate analysis,the incidence of composite endpoints through 30 days and 1 year of follow-up was significantly higher in the abnormal group than in the normal group(P<0.05).By multivariate analysis,adjusted for hypertension,diabetes mellitus,hyperlipaemia,previous MI,electrocardiogram(ECG) changes and etc.,high cTnI maintained a strong association with the risk of composite cardiac events through 30 days of follow-up[odds ratio(OR),8.175;95% confident interval(CI),1.014-65.917;P<0.05]as well as through 1 year of follow-up(OR,2.612;95% CI,1.164-5.859;P<0.05)in all three groups.Conclusions We have testified Beckman Coulter ACCESS AccuTnI assay had high sensitivity and specificity in the diagnosis of NSTEMI.Detection of plasma cTnI is of clinical value for prognosis of NSTEACS.

Evaluation of clinical performance of cardiac troponin Ⅰ in diagnosis and prognosis of non-ST elevation acute coronary syndromes